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Abstract 
Genetic case-control association studies are often based upon clinically 
ascertained cases and population or convenience controls. It is known that some 
of the controls will contain cases, as they are usually not screened for the disease 
of interest. However, even clinically assessed cases and controls can be 
misassigned. For Alzheimer’s disease (AD) it is important to know the accuracy 
of the clinical assignment.  The predictive accuracy of Alzheimer’s disease risk by 
polygenic risk score analysis has been reported in both clinical and 
pathologically confirmed cohorts. The genetic risk prediction can provide 
additional insights to inform classification of subjects to case and control sets at 
a preclinical stage. In this study we take a mathematical approach and aim to 
assess the importance of a genetic component for the assignment of subjects to 
AD positive and negative groups, and provide an estimate of misassignment 
rates in AD case/control cohorts accounting for genetic prediction modelling 
results. The derived formulae provide a tool to estimate misassignment rates in 
any sample. This approach can also provide an estimate of the maximal and 
minimal misassignment rates and therefore could be useful for statistical power 
estimation at the study design stage. We illustrate this approach in two independent 
clinical cohorts and estimate misdiagnosis rate up to 36% in controls unscreened for 
the APOE genotype, and up to 29% when E3 homozygous subjects are used as 
controls in clinical studies. 
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Introduction 
Genetic case-control association studies are often based upon clinical assessment 
of cases and population or convenience controls. It is clearly the case that some 
of the controls can potentially contain patients in the early stage of disease, as 
they are not typically screened for the disease. It is assumed that the number of 
controls, who are actually cases, is relatively small and can be estimated by the 
prevalence of the disease in the population (e.g. ~3% lifetime prevalence of AD).  
Polygenic risk score (PRS) analysis enhances the predictability of the diagnosis 
of AD [Escott-Price et al. (2015)]. The largest contributors to AD risk analysis, 
the E4 allele (risk) and the E2 allele (protective) gave AUC of 0.68 (E4 alone) and 
0.69 (E4+E2) as compared to overall PRS AUC=0.75 in clinical cohorts [ibid].  In a 
recent PRS analysis, we showed that the area under the curve (AUC) in a 
pathologically confirmed case/control series was 0.84 [Escott-Price et al. 
(2017)]. In addition, in a case/control sample of pathologically confirmed 
individuals who carry neither the E4 or E2 allele (i.e. E3 homozygotes), the PRS 
gave AUC ~0.83 [95% CI: 0.80-0.86]) [Escott-Price et al. (2018)]. When this was 
tested in clinical series the AUC was reduced from 0.75 in the whole dataset to 
0.65 in E3 homozygotes [ibid]. This reduction in PRS in the clinical but not 
pathological series is indicative of a substantial misassignment rate in the 
former. 
A study at the National Institute on Aging Alzheimer Disease Centers [Beach et al. 
(2012)] had reported measures of agreement between stratified levels for the 
clinical and neuropathologic diagnosis of AD in a sample of 919 subjects, who 
were classified based on their clinical categorization as ‘‘probable AD,’’ ‘‘possible 
AD,’’ or ‘‘not AD.’’  The ‘‘not AD’’ group included non-AD dementias and subjects 
with no dementia were excluded. The highest sensitivity (87.3%) reported in 
[Beach et al. (2012)], was when the clinical diagnosis was defined as clinically 
probable or possible AD, and neuropathologic AD definition was defined as 
“frequent neuritic plaque density score” and Braak neurofibrillary tangle stage V 
or VI. In practice, most of the cases in clinical case/control samples are collected 
with “probable AD” diagnosis. For this combination of clinical and 
neuropathologic criteria, analysis of mismatched clinical and neuropathologic 
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diagnoses provides sensitivity of 76.6% [Beach et al. (2012)]. This means that 
when the clinical diagnosis was defined as probable AD and the neuropathologic 
diagnosis as frequent neuritic plaques with Braak stage V-VI, 23.4% of people 
did not have frequent neuritic plaque density, despite their positive clinical 
diagnoses. Furthermore, more than a third of APOE E4 non-carriers with clinical 
diagnosis of mild-to-moderate Alzheimer’s dementia, had minimal Alzheimer’s 
disease plaque accumulation in cerebral cortex [Monsell et al. (2015)]. 
In this study we aim to estimate misassignment rate in controls based upon 
genetic prediction accuracy in clinical and neuropathology confirmed samples of 
AD cases and controls. This is necessitated by the frequently asked question 
“what proportion of controls are actually early cases”, when dealing with GWAS 
results?  In this analysis we seek to answer that question. We derive 
mathematical formulae to compare case/control classification by clinical 
diagnosis and true pathology status accounting for a hidden layer of genetic 
classification between diseased subjects and controls.  These formulae were used 
to illustrate the potential misassignment rates in clinical data samples, using the 
reported values of prediction (by PRS) accuracy in AD pathology confirmed 
samples of cases and controls [Escott-Price et al. (2017)].  
Methods 
Derivation of misassignment rate estimates in a clinical sample. 
Misassignment rate was calculated using derived analytical formulae based on 
sensitivity and specificity. We first constructed three 2x2 contingency tables 
(also known as confusion matrices in the prediction modelling field), describing: 
1) clinical AD diagnosis (case/control) vs PRS prediction (yes/no) in a clinical 
sample, 2) pathologically confirmed AD status (yes/no) vs PRS prediction 
(yes/no), and 3) pathologically confirmed AD status vs clinical diagnosis. The 
latter table was expressed in terms of prediction accuracy measures (sensitivity, 
specificity, positive predictive value (PPV) and negative predictive value (NPV)), 
estimated from clinical and pathologically confirmed samples (see Appendix 1). 
The numerical results that we provide in this paper are entirely derived from 
estimates made in previous publications. The estimates can be entirely 
populated using the clinical case/control numbers of the study. 
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Samples used for illustration of misassignment rates estimation 
We applied the derived formulae and estimated misassignment rates in two 
independent clinical cohorts. The first is the Genetic and Environmental Risk in 
Alzheimer's Disease (GERAD) consortium data [Harold et al. (2009)]. This is the 
first account where the prediction utility of AD PRS was reported. The best 
prediction accuracy using PRS was achieved when SNPs were pruned for linkage 
disequilibrium with parameters r2=0.1 and a window of 1000kb, and the most 
strongly associated AD SNPs with p-values≤0.5 were included in the individual 
PRS.  The other independent dataset was The Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) dataset. This is a publically available database 
(http://www.loni.ucla.edu/ADNI/) which started in 2004 and contains genetic, 
imaging and biomarker data for about 900 individuals between the age of 55 and 
90. Clinical diagnosis and genetic information were available for 770 individuals, 
who were either already diagnosed with AD (N=47) or had mild cognitive 
impairment (MCI) (N=459) or healthy controls (N=262) at baseline. We 
generated PRS for the ADNI participants in the same way as for GERAD data, 
using IGAP stage 1 [Lambert et al. (2013)] summary statistics to inform AD PRS.  
For prediction accuracy estimates in a pathologically confirmed sample, we used 
sensitivity/specificity/PPV/NPV estimates reported in [Escott-Price et al. 
(2017)] for a pathologically confirmed sample of 1,011 cases and 583 controls. 
This series was obtained from 21 National Alzheimer’s Coordinating Center 
(NACC) brain banks and from the Miami Brain Bank as previously described 
[Corneveaux et al., 2010; Myers et al., 2007; Petyuk et al., 2018; Webster et al., 
2009]. Our criteria for inclusion were as follows: self-defined ethnicity of 
European descent (in an attempt to control for the known allele frequency 
differences between ethnic groups), neuropathologically confirmed Alzheimer’s 
disease or no neuropathology present, and age of death greater than or equal to 
65. Neuropathological diagnosis was defined by board-certified 
neuropathologists according to the standard NACC protocols [Beekly et al., 
2004]. Samples derived from subjects with a clinical history of stroke, 
cerebrovascular disease, Lewy bodies, or comorbidity with any other known 
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neurological disease were excluded. Alzheimer’s disease or control 
neuropathology was confirmed by plaque and tangle assessment with 45% of the 
entire series undergoing Braak staging [Braak and Braak, 1995]. Samples were 
de-identified before receipt, and the study met human studies institutional 
review board and HIPPA regulations. This work is declared not human-subjects 
research and is IRB exempt under regulation 45 CFR 46. 
To estimate the misassignment rate in controls, the analytical formulae require 
us to fix the parameter of AD misdiagnosis rate in cases. Since most cases in 
clinical case/control samples are collected with clinically “probable AD” or 
“probable or possible AD” diagnosis, and in the pathology confirmed study 
[Escott-Price et al. (2017)] the neuropathologic criterion for cases was Braak 
stage V or VI, we used sensitivity of 76.6% and 87.3% for AD misdiagnosis rates 
as reported in [Beach et al. (2012)]. In addition, according to [Escott-Price et al. 
(2018)], among APOE E4 non-carriers with the clinical diagnosis of mild-to-
moderate AD, 37% had minimal neuritic plaques, and we used this value as an 
approximation of the misdiagnosis rate in the E3 homozygous cases.  
 
Results 
Estimation of misdiagnosis rates in a clinical sample 
Assume that in a sample of � clinically screened subjects (����(�)  cases and ����(�)  
controls), ����(�) and ����(�)  are the numbers of true cases and controls, that will be 
pathology confirmed (we use superscripts “(c)” and “(p)” to distinguish between 
the numbers of clinically and pathology based classifications, respectively).  The 
range for the number of subjects who were clinically and neuropathologically 
confirmed as having AD are between max�0,����(�) −  ����(�) � and min�����(�) ,����(�)�. 
This means that in the worst case scenario, all clinical cases are in fact unaffected 
(zero overlap), and in the best case scenario all clinical cases were given the 
correct diagnosis and will be confirmed neuropathologically. Similarly, the range 
for the number of controls who were also neuropathologically confirmed as “no 
AD” is between max�0,����(�) − ����(�) � and min�����(�) ,����(�)�. In reality, the number 
will lie somewhere in this range. To calculate these numbers in real data, we use 
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values of prediction/classification accuracy reported in actual case/control 
studies. 
For a clinical sample the best PRS prediction accuracy (Area Under the Curve) 
was reported as AUC=0.75 with sensitivity and specificity ��(�) = ��(�) = 0.69 
[Escott-Price et al. (2015)]. The PRS prediction accuracy values in a 
pathologically confirmed sample of cases and controls were published in [Escott 
Price et al. (2017)] as ��(�) = ��(�) = 0.79, and ���(�) = 0.69. (The latter 
numbers however might be marginally overestimated, due to the 3% overlap of 
the discovery and test samples used in [Escott Price at al. (2017)].)  Using these 
prediction accuracy values, we construct the confusion matrices (tables A1 and 
A2 in Appendix 1) in the clinical sample [Escott-Price et al. (2015)] of the total of � = 4,603 (3,049 Alzheimer’s disease cases and 1,554 controls) individuals, as: 
 Table 1. 
Clinical diagnosis (GERAD) 
 
 Table 2. Pathologically 
confirmed status (derived 
estimates)  
G
en
et
ic
 t
es
t  Yes No  Yes No 
Yes � =2096 � =485 � =2285 � =359 
No � =953 � =1069 � =607 � =1352 
Total ����(�)=3049 ����(�) =1554 ����(�)=2892 ����(�) =1711 
 
From these two tables we cannot simply imply that out of 3,049 clinical cases, 
2,892 cases will be pathologically confirmed, as some subjects, who are 
unaffected according to the clinical assessment, may actually have AD. Using 
sensitivity of 76.6% reported in [Beach et al. (2012)], we estimate the number of 
true cases (which were clinically diagnosed as AD and expected also be 
pathologically confirmed) 3,049*0.766 ≈2,336 (denoted as � in Appendix). Then 
the number of controls which expected to be pathologically confirmed is ����(�) −����(�) + � =1,554 - 2,892 + 2,335 = 998 (denoted as � in the equation (1) in 
Appendix). Finally, in this sample we obtain the misassignment rate (MAR) in 
controls MAR=557/1554=0.36 (see equation (2) in Appendix 1).  
For E3 homozygous subjects in the clinical cohort [Escott Price et al. (2015)], the 
genetic based prediction AUC was lower (AUC=0.65) with sensitivity and 
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specificity ��(�) = ��(�) = 0.60 (N cases=1,090 and N controls=947). The values 
of the genetic prediction accuracy measures in pathologically confirmed sample 
[Escott-Price et al. (2017)] were ��(�) = ��(�) = 0.745, and ���(�) = 0.768. 
Clinical AD misdiagnosis rates in non-carriers of the apolipoprotein E4 allele are 
higher for subjects who are unscreened for E4 alleles. Using 37% as the 
approximation to AD misdiagnosis rate for E3 homozygous individuals [Monsell 
et al. (2015)], gives the misassignment rate in controls of about 29% clinical 
samples [Escott-Price et al. (2015)].  That is, about 29% of persons assigned as 
controls in the clinical series at the age of these series (late 70s), are in the early 
stages of disease. 
In an attempt to replicate our result in an independent sample we used the ADNI 
data. The ADNI cohort is older than GERAD; the mean age in the GERAD sample 
was 73.8 [SD=8.6] and 71.4 [SD=11.1], and the mean age in the ADNI sample at 
the last point of assessment was 78.4 [SD=7.1] and 78.9 [SD=7.6], in cases and 
controls respectively. Similarly to Tables 1 and 2, Tables 3 and 4 present the 
results for ADNI data. In this dataset we estimated the PRS for each individual as 
described in [Escott-Price et al. (2015)] and calculated ��(�) = ��(�) = 0.678, 
PPV=0.621, NPV=0.731, AUC=0.747).  The values of the genetic prediction 
accuracy measures in pathologically confirmed sample [Escott-Price et al. 
(2017)] were ��(�) = ��(�) = 0.79, and ���(�) = 0.686. To estimate the 
misassignment rate in controls with our analytical approach, we used sensitivity 
value 87.3%, which corresponds to the oldest group of people (83.2 years) with 
“clinically probable or possible” AD in the [Beach et al. (2012)] paper. Our 
analytical approach gives the misassignment rate in controls of 44.6%. The R 
code detailing these analyses is presented in Appendix 2. 
 Table 3. 
Clinical diagnosis (ADNI) 
 
 Table 4. Pathologically 
confirmed status (derived 
estimates)  
G
e
n
e
ti
c 
te
st
 
 Yes No  Yes No 
Yes � =118 � = 72 � = 199 � = 31 
No � =56 � =152 � =53 � =116 
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Total ����(�) =174 ����(�) =224 ����(�)=252 ����(�) =147 
 
In these data we have also attempted to directly calculate misassignment rates in 
controls. There were 262 controls available at baseline assessment. On average 
within 4.7 years, 15 people have progressed to AD, 47 people have developed 
mild cognitive impairment (MCI), and 200 individuals did not change their 
diagnosis. This suggests the current misassignment rate is in between 5.7-21.7%. 
The mean age of the progressors was 75.2 [4.0], and for those who did not 
progress the average age was 74.1 [SD=5.7] years at the baseline of assessment. 
However, since AD is age dependent, it is expected that more controls will 
progress to AD when they reach age 85+. The incidence rate of AD increases 
almost exponentially with increasing age until 85 years of age. It is still debated 
whether the incidence will further increase at more advanced ages or will reach 
a plateau at a certain age [Qiu et al., 2009]. Since there were only 5 individuals of 
age 85+ in the ADNI data at the baseline, we were unable to estimate incidence 
rates directly. Here we used incident rates estimates (~55 persons per 1000-
years at age 85+) reported by [Qiu et al., 2009]. Thus we can expect an additional 
55% of the sample to develop AD after 10 years, which is slightly above of the 
analytical estimate (44.6%). 
 
Discussion 
It has been reported that Alzheimer’s disease misclassification rates range 
between 14%-37% depending on the exact clinical and neuropathologic criteria 
used and whether the individuals were screened for APOE E4 alleles [Beach et al. 
(2012), Monsell et al. (2015)]. In addition, recent clinical trials show that 20% of 
all patients (and more than 33% of those who were non-carriers of the 
apolipoprotein E4 allele) with mild-to-moderate Alzheimer’s dementia did not 
show an elevation in amyloid on positron emission tomography (PET) imaging 
[Salloway et al. (2014), Doody et al. (2014)]. 
Conducting an actual autopsy based study on unaffected individuals, aiming to 
identify AD cases among them, is difficult to justify unless it is a part of a large 
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population screening study. Here we use the genetic prediction findings to 
mathematically estimate the misassignment in controls. Our earlier results show 
that the prediction accuracy of PRS in the pathologically confirmed sample of E3 
homozygotes carriers is high and equivalent to the prediction accuracy in the 
samples of the whole dataset [Escott Price et al. (2017) and under review], 
indicating that APOE is an independent risk factor for the disease. Therefore, we 
argue that it is not sufficient just to screen for APOE to classify subjects, for 
example, in AD clinical trials. 
In this study we derive analytical formulae to estimate misassignment rates in 
clinical studies. These formulae are based upon sensitivity, specificity, PPV and 
NPV estimated from clinical and pathologically confirmed studies. However, the 
PPV and NPV estimates must be adjusted according to the case/control ratio of 
the clinical study for which misassignment rates are being estimated (unless the 
ratios are equal), and here we show how to calculate sample prevalence adjusted 
PPV and NPV. To demonstrate how these equations can be used in practice, we 
calculate misalignment rates in two independent clinical cohorts. Our headline 
figures are of course dependent on the quantities reported in previous studies. 
However, the approach is generalisable to other studies, and the misassignment 
rates can be easily recalculated. 
Our results show that the misassignment rates in controls in clinical case-control 
studies is likely to be high (~30%). It would be expected to see an increased 
number of actual controls among E3 homozygous subjects as those individuals 
do not carry the strongest AD predictor.  Indeed, the negative predictive value, or 
the percentage of correctly predicted controls, in the pathology confirmed 
sample is higher than in clinical cohort (NPV=0.77 and 0.57 in pathology 
confirmed and clinical samples, respectively). However, the misdiagnosis rate of 
cases in E3 homozygotes is high (37%), which implies reduced but still relatively 
high rates of misassignments, as compared to the sample not screened for APOE 
(29% vs 36%, respectively). 
In the ADNI data, there were 262 controls available, of them 15 progressed to 
AD, 47 developed MCI and 200 did not. This suggests a misassignment rate 
between 8.0-23.7%, however, as AD is age dependent, it is expected that more 
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controls will progress to AD when they reach age 85+ (prevalence of AD is 18% 
and 33% in 70-85 and 85+, respectively). Projecting the latter prevalence to this 
data, the misassignment rate expected is about 40%, which is similar to our 
estimates. 
These levels of misassignment rates in both cases and controls reduce not only 
the power of statistical analyses in case/control series but also the PRS 
prediction accuracy in clinical samples.  In biomarker studies of Alzheimer’s 
disease, they suggest that no biomarker will be able to give clean separations 
between those diagnosed with disease and those designated as controls since 
considerable proportions of both categories will be misclassified.  As CSF and 
blood biomarkers of disease are assessed in clinical series, this inevitable 
misclassification, with ~30% of both cases and ~30% of controls being 
categorised in the wrong group. 
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Appendix 1. 
Assume that in a sample of � total subjects, the proportion of clinical cases is 
known (�). Then the numbers of “clinical cases” and “clinical controls” are ����(�) =�� and ����(�) = (1 − �)�, respectively. We further assume that a genetic test, e.g. 
PRS, divides the subjects into two groups called “predicted clinical cases” and 
“predicted clinical controls” with sensitivity ��(�) and specificity ��(�). Then all 
entries of the “clinical” classification table (Table A1) can explicitly be calculated.  
Table A1. Classification table comparing genetic test outcome with clinical 
diagnosis.  
 Clinical diagnosis  
G
en
et
ic
 t
es
t 
 Yes No Total 
Yes � = ����(�) � = �(1 − �)�1 − ��(�)� � + � 
No � = ��(1 − ��(�)) � = �(1 − �)��(�) � + � 
Total � + � = ��=����(�)  � + � = �(1 − �)=����(�)  � 
 
Table A2 is the classification table for pathologically confirmed cases and 
controls in the same hypothetical sample of � subjects, where A, B, C and D 
values are the number of true positive, false positive, false negative and true 
negative predictions by genetic information, respectively.  These values are 
unknown, however, the prediction accuracy estimates which compare 
pathologically confirmed disease status with genetic prediction, can be obtained 
from published studies (e.g. for AD, [Escott-Price et al. (2017)]). Let ��(�), ��(�), ���(�) and ���(�) (sensitivity, specificity, positive and negative predictive 
values, respectively) be known.  
Note that in this calculation we use PPV and NPV values derived directly from 
the clinical samples, and these values therefore are dependent on the 
case/control ratio. For example  for Table A1, ��� = ��+ �, therefore ��� =���(�)���(�)+ (1−�)�1−��(�)�, where f is the proportion of clinical cases in the sample 
(similar, ��� = (1−�)��(�)�(1−��(�))+ (1−�)��(�) ). If the known PPV and NPV values are 
prevalence-adjusted (����), then before others can use this approach to make 
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similar predictions from their own clinical studies, the PPV and NPV need to be 
adjusted accounting for the case/control ratio for their particular clinical study. 
The prevalence-adjusted ��������� and  ��������� values are derived using Bayes' theorem: ��������� = ��(�)������(�)����+�1−��(�)�(1−����)  and  ��������� = ��(�)(1−����)(1−��(�))����+��(�)(1−����). Then PPV 
and NPV can be expressed in terms of sensitivity, specificity, prevalence and the 
propotrtion of cases in the sample  ratio as ��� = ����������(1−����)
(1−�)����−���������(����−�) and ��� = ���������(1−�)�����(1−����)−���������(�−����). 
 
Table A2. Classification table comparing genetic test outcome with true 
pathologically confirmed status. 
 Pathologically confirmed status  
G
en
et
ic
 t
es
t 
 Yes No Total 
Yes � � � + � 
No � � � + � 
Total � + � = ����(�) � + � = ����(�)  � 
 
The sensitivity, specificity and negative predictive values are defined as ��(�) = ��+�,  ��(�) = ��+�, ���(�) = ��+�. Together with the expression for the 
total number of subjects, � = � + � + � + �, the entries of the Table A2 can be 
calculated as   � = � �γ , � = ��, � = ��,  � = �1+�+�+�γ  , 
where  � = 1−��(�)��(�) ,  � = 1−���(�)���(�) , and γ = 1−��(�)��(�) .  
Finally, to identify how many controls are likely to be pre-cases in the clinical 
sample and vice versa, we construct Table A3, which compares clinical diagnosis 
with pathologically confirmed status. In Table A3, � is the number of subjects 
whose clinical diagnosis is correct (i.e. will be pathologically confirmed as having 
AD), and � is the number of healthy controls who will die without AD.  
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Table A3. Classification table comparing clinical diagnosis with true 
pathology status. 
 Pathologically confirmed status  
C
li
n
ic
al
 d
ia
g
n
o
si
s 
 Yes No Total 
Yes � � + � − �  � + � = ����(�)  
No 
     � + � − �  
= � + � − � �  � + � = ����(�)  
Total � + � = ����(�) � + � = ����(�)  � 
 
The numbers of correctly assessed controls are 
y = ����(�) − ����(�) + � ,                                       (1) 
and the misassignment rate (MAR) in controls is ��� = �����(�) − �� /����(�)  .                                     (2) 
Note for both equations (1) and (2), the number of true positive cases, �, needs 
to be defined.  
Since all entries of this table represent the number of people and thus are 
positive, the range of values for � is between max�0,����(�) −  ����(�) �  and 
min�����(�) ,����(�)� , and the range of values for � is between max�0,����(�) − ����(�) �  
and  min�����(�) ,����(�)� .  
When the misdiagnosis rate in cases is at its maximum (i.e. value of �=0 or ����(�) −  ����(�)  , if the number of pathologically confirmed cases is greater than the 
number of clinically assessed controls), then the misassignment rate in controls 
is also at its maximum: either  � = 0, i.e. all controls (after a pathology check) 
have initially been incorrectly diagnosed as cases, or � = ����(�) − ����(�), i.e. all 
pathologically confirmed cases were considered as controls in the clinical 
sample. The best case scenario is when � is at its maximum, i.e. all clinical 
diagnoses of cases were correct. Then � is at its maximum too, i.e. all controls in 
the clinical sample were pathology confirmed as clear of AD, or all subjects 
confirmed as “clear” were correctly assigned to the control group. 
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Table A4 demonstrates these two scenarios for a real sample of 4,603 subjects 
(3,049 cases and 1,554 controls, according to clinical assessment) [Escott-Price 
et al. (2015)]. The proportion of cases is � = 0.66. In this sample the best AUC 
(Area Under the Curve) was reported as 0.75, the sensitivity and specificity ��(�) = ��(�) = 0.69 [Escott-Price et al. (2015)]. Prediction accuracy estimates 
which compare pathologically confirmed disease status with genetic prediction 
are  ��(�) = ��(�) = 0.79, and ���(�) = 0.69 [Escott-Price et al. (2017)]. Tables 
A1 and A2 then look as follows: 
 Clinical diagnosis 
(Table A1) 
 Pathologically confirmed status 
(Table A2) 
G
en
et
ic
 t
es
t 
 Yes No  Yes No 
Yes � =����(�)=2096 � =485 � =2285 � =359 
No � =953 � =1069 � =607 � =1352 
Total ����(�)=3049 ����(�) =1554 ����(�)=2892 ����(�) =1711 
 
From these two tables we cannot simply imply that out of 3,049 clinical cases, 
2,892 cases were pathologically confirmed, as some subjects, which are 
unaffected according to the clinical assessment, may actually be pathologically 
confirmed AD cases. 
When � (Table A3), is at its minimum, i.e. the misdiagnosis rate in cases is at 
maximum, then � = 0, i.e. all pathologically confirmed controls have been 
incorrectly clinically diagnosed as cases. In our real example min(�) =1,338, 
which corresponds to the worst case scenario, the highest possible misdiagnosis 
rates 56% and 100% in cases and controls, respectively (see left section of Table 
A4).  
The best case scenario is when � is at its maximum (right section of Table A4). In 
our example max(�) =2,892. Then the misdiagnosis rate in cases is only 5%, and 
all subjects, clinically seen as controls, were pathologically confirmed as controls 
(misdiagnosis rate in controls is 0%).   
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Table A4. Hypothetical best and worst scenarios of misclassification of 
clinical and neuropathologic diagnoses of AD. 
 Pathologically confirmed status 
 
 
 
 
Worst scenario 
 
Best scenario 
 
Total 
C
li
n
ic
al
 d
ia
g
n
o
si
s 
Yes No  Yes No  
Yes 1338 1711 
 
2892 157 ����(�)=3049 
No 1554 0 
 
0 1554 ����(�) =1554 
Total ����(�)=2892 ����(�) =1711  ����(�)=2892 ����(�) =1711 N = 4603 
 
Appendix 2. Illustration of misassignment rates estimation in ADNI data 
with R script. 
 
#TABLE A1 
Ncas<-174 
Ncon<-224 
N<-Ncas+Ncon 
 
mat<-matrix(c(118,56,72,152), ncol=2) 
Sens<-mat[1,1]/sum(mat[,1]); Sens 
Spec<-mat[2,2]/sum(mat[,2]); Spec 
PPV<-mat[1,1]/sum(mat[1,]); PPV 
NPV<-mat[2,2]/sum(mat[2,]); NPV 
sum(mat) 
 
alpha<-(1-Spec)/Spec 
beta <-(1-NPV )/NPV 
gamma<-(1-Sens)/Sens 
 
d<-N/(1+alpha+beta+beta/gamma) 
a<-d*beta/gamma 
b<-d*alpha 
c<-d*beta 
clinical<-matrix(c(a,c,b,d), ncol=2) 
clinical<-round(clinical) 
 
#TABLE A2 
Sens<-0.79 
Spec<-0.79 
PPV<-0.867 
NPV<-0.686 
 
alpha<-(1-Spec)/Spec 
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beta <-(1-NPV)/NPV 
gamma<-(1-Sens)/Sens 
 
D<-N/(1+alpha+beta+beta/gamma) 
A<-D*beta/gamma 
B<-D*alpha 
C<-D*beta 
path.conf<-matrix(c(A,C,B,D), ncol=2) 
path.conf<-round(path.conf) 
 
clinical 
path.conf 
 
 
#TABLE A3 
f<-0.873 #sensitivity of 87.3% as reported in [Beach et al 2012] 
t3<-matrix(0, ncol=2, nrow=2) 
x<-round(f*(a+c)) 
t3[1,1]<-x 
t3[1,2]<-a+c-x 
t3[2,1]<-A+C-x 
t3[2,2]<-x-A-C+b+d  
t3<-abs(round(t3)); t3 
 
#cases misdiag rate: 
t3[1,2]/(t3[1,1]+t3[1,2]) 
#controls misdiag rate: 
t3[2,1]/(t3[2,1]+t3[2,2]) 
